Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of Ozempic and Wegovy, alleging the drugmaker failed to report potential side effects in patients who took the popular GLP-1 medications in a timely manner
When patients experience itching during GLP-1 therapy, the cause is often unrelated to the medication itself
For a detailed breakdown of how to select your specific dose, see our NAD+ dosage guide
When present, atrial fibrillation should be treated with anticoagulation to prevent risk of thromboembolic complications
Safety and Tolerability Preclinical studies suggest that 5-Amino-1MQ is well-tolerated with a favorable safety profile
This article reviews the molecular mechanism of mitophagy, focusing on the specific regulatory role of mitophagy in microvascular complications of diabetes and the existing research progress in this field